A5002542554- SARS-CoV-2 and COVID-19 Research
- Immunodeficiency and Autoimmune Disorders
- Poxvirus research and outbreaks
- Herpesvirus Infections and Treatments
- Bacillus and Francisella bacterial research
- Viral gastroenteritis research and epidemiology
- Respiratory viral infections research
- Virus-based gene therapy research
- Vaccine Coverage and Hesitancy
- Influenza Virus Research Studies
- Hepatitis Viruses Studies and Epidemiology
- Immunotherapy and Immune Responses
- Animal Virus Infections Studies
- Mosquito-borne diseases and control
- COVID-19 Clinical Research Studies
- Immune responses and vaccinations
- Viral Infections and Vectors
- Heparin-Induced Thrombocytopenia and Thrombosis
- Hepatitis B Virus Studies
- Global Health Care Issues
- Viral Infections and Outbreaks Research
- Health Systems, Economic Evaluations, Quality of Life
- Glycosylation and Glycoproteins Research
- Plant Virus Research Studies
- Clostridium difficile and Clostridium perfringens research
Erasmus MC
2020-2025
University of Cape Town
2025
Groote Schuur Hospital
2025
Erasmus University Rotterdam
2020-2024
Radboud University Medical Center
2023
Radboud University Nijmegen
2023
Misgav Ladach
2022
Universidad de Salamanca
2022
In July 2022, the ongoing monkeypox (MPX) outbreak was declared a public health emergency of international concern. Modified vaccinia Ankara-Bavarian Nordic (MVA-BN, also known as Imvamune, JYNNEOS or Imvanex) is third-generation smallpox vaccine that authorized and in use against MPX. To date, there are no data showing MPX virus (MPXV)-neutralizing antibodies vaccinated individuals nor efficacy Here we show MPXV-neutralizing can be detected after MPXV infection historic vaccination....
Patients with inborn errors of immunity (IEI) are at increased risk severe coronavirus disease-2019 (COVID-19). Effective vaccination against COVID-19 is therefore great importance in this group, but little known about the immunogenicity vaccines these patients.We sought to study humoral and cellular immune responses after mRNA-1273 adult patients IEI.In a prospective, controlled, multicenter study, 505 IEI (common variable immunodeficiency [CVID], isolated or undefined antibody...
Abstract Waning antibody responses after COVID-19 vaccination combined with the emergence of SARS-CoV-2 Omicron lineage led to reduced vaccine effectiveness. As a countermeasure, bivalent mRNA-based booster vaccines encoding ancestral spike protein in combination that BA.1 or BA.5 were introduced. Since then, different BA.2-descendent lineages have become dominant, such as XBB.1.5, JN.1, EG.5.1. Here, we report post-hoc analyses data from SWITCH-ON study, assessing how priming regimens...
Patients with inborn errors of immunity (IEI) are at increased risk severe coronavirus disease-2019 (COVID-19). Effective long-term protection against COVID-19 is therefore great importance in these patients, but little known about the decay immune response after primary vaccination. We studied responses 6 months two mRNA-1273 vaccines 473 IEI patients and subsequently to a third mRNA vaccine 50 common variable immunodeficiency (CVID).In prospective multicenter study, (including X-linked...
Previous studies have demonstrated that the majority of patients with an inborn error immunity (IEI) develop a spike (S)-specific IgG antibody and T-cell response after two doses mRNA-1273 COVID-19 vaccine, but little is known about to booster vaccination. We studied immune responses 8 weeks vaccination mRNA-based vaccines in 171 IEI patients. Moreover, we evaluated clinical outcomes these one year start Dutch campaign. This study was embedded large prospective multicenter investigating...
Dengue is the most rapidly spreading vector-borne disease worldwide, with over half global population at risk for an infection. Antibody-dependent enhancement (ADE) associated increased severity and may also be attributable to deterioration of in vaccinated people. Two dengue vaccines are approved momentarily, more development. The increasing use against dengue, combined development more, makes a thorough understanding processes behind ADE important than ever. Above that, due lack treatment...
In response to the mpox outbreak in 2022 and 2023, widespread vaccination with modified vaccinia Ankara-Bavarian Nordic (MVA-BN, also known as JYNNEOS or Imvanex) was initiated. Here, we demonstrate that orthopoxvirus-specific binding MVA-neutralising antibodies waned undetectable levels 1 year post at-risk individuals who received two doses of MVA-BN administered subcutaneously an interval 4 weeks, without prior smallpox vaccination. Continuous surveillance is essential understand impact...
Background CVID patients present an increased risk of prolonged SARS-CoV-2 infection and re-infection a higher COVID-19-related morbidity mortality compared to the general population. Since 2021, different therapeutic prophylactic strategies have been employed in vulnerable groups (vaccination, monoclonal antibodies antivirals). The impact treatments over last 2 years has not explored international studies considering emergence viral variants management between countries. Methods A...
Abstract In July 2022, the ongoing monkeypox (MPX) outbreak was declared a public health emergency of international concern by World Health Organization. Modified vaccinia virus Ankara (MVA-BN, also known as Imvamune, Jynneos, or Imvanex) is 3 rd generation smallpox vaccine that generated serial passaging more pathogenic parental (VACV), and authorized against MPX in humans two-shot regimen. Up to now, there lack data demonstrate (MPXV)-neutralizing antibodies vaccinated individuals efficacy...
Abstract Background Affordability and accessibility of hospital care are under pressure. Research on financing focuses primarily incentives in the financial system outside hospital. It is notable that little known about (incentives in) internal funding hospitals. Therefore, our study budget allocation hospitals: distribution model. Based hypothesis reimbursement models hospitals might interact, we gain knowledge about-, insight into, interaction different used Dutch hospitals, how they...
Antibodies have a key role in the immune system, making their characterization essential to biomedical, biopharmaceutical, and clinical research questions. Antibody effector functions are mainly controlled by quantity, subclass, Fc glycosylation. We describe an integrated method measure these three critical dimensions simultaneously. The subclass-specific immunoglobulin G (IgG) glycosylation analysis combines immunosorbance with glycopeptide-centered LC-MS detection. For IgG1-specific...
Summary Waning antibody responses after COVID-19 vaccination combined with the emergence of SARS-CoV-2 Omicron lineage led to reduced vaccine effectiveness. As a countermeasure, bivalent mRNA-based booster vaccines encoding ancestral spike protein in combination that BA.1 or BA.5 were introduced. Since then, BA.2-descendent lineages have become dominant, such as XBB.1.5 BA.2.86. Here, we assessed how different priming regimens affect immunogenicity recently used vaccinations and breakthrough...
Abstract In response to the 2022-2023 mpox outbreak, widespread vaccination with modified vaccinia Ankara-Bavarian Nordic was initiated. Here, we demonstrate that orthopoxvirus-specific binding and MVA-neutralizing antibodies wane undetectable levels one year post-vaccination in at-risk individuals without pre-existing immunity. Continuous surveillance is essential understand impact of declining antibody levels.
Healthcare workers (HCW) are at increased risk of contracting hepatitis B virus (HBV) and are, therefore, vaccinated pre-exposure. In this study, the HBV vaccination programme for medical students in a university hospital Netherlands was evaluated. first part, effectiveness programme, which consisted with Engerix-B® 0, 1, 6 months, retrospectively evaluated over 7 years (2012–2019). second part we followed (the 2019 cohort) who had previously been against (4–262 months prior to primary...
Summary Background Bivalent mRNA-based COVID-19 vaccines encoding the ancestral and Omicron spike protein were developed as a countermeasure against antigenically distinct SARS-CoV-2 variants. We compared (variant-specific) immunogenicity reactogenicity of bivalent BA.1 in individuals who primed with adenovirus- or vaccines. Methods In this open-label, multicenter, randomized, controlled trial, healthcare workers Ad26.COV2.S boosted mRNA-1273.214 BNT162b2 OMI BA.1. The primary endpoint was...